Reese’s Brand Creates the Ultimate Team to Support the Ultimate Cup

23x U.S. Olympic Gold Medalist and Swimming Legend, Michael Phelps, 5x U.S. Olympic Gold Medalist, Katie Ledecky and 2x U.S. Olympic Gold Medalist Caeleb Dressel form the Ultimate Team Reese’s

PR Newswire

HERSHEY, Pa., April 12, 2021 /PRNewswire/ — It’s nearly 100 Days from the long-awaited, much-anticipated Olympic Games Tokyo 2020 and the Reese’s brand is proud to announce the Ultimate Team. The perennial chocolate and peanut butter powerhouse is partnering with three of the greatest U.S. Olympic athletes to grace the Games, Team USA and the sport of swimming: Michael Phelps, Katie Ledecky and Caeleb Dressel.  Phelps, Ledecky & Dressel will band together to support Big Orange and form the Ultimate Team Reese’s.

Starting with legendary Michael Phelps, 23x U.S. Olympic Gold Medalist – and Reese’s aficionado – Michael will be the face of the Reese’s brand this summer appearing in a new ad campaign highlighting the newest member of the Reese’s family, Reese’s Ultimate Lovers Cup.

Rounding out the Ultimate Team Reese’s will also include two world-record swimming dynamos, and Tokyo 2020 hopefuls, 5x U.S. Olympic Gold Medalist Katie Ledecky and 2x U.S. Olympic Gold Medalist Caeleb Dressel.

“As America’s number one chocolate brand, we couldn’t settle for anything other than the best and that’s exactly why we’ve partnered with these legendary U.S. Olympians: Michael Phelps, Katie Ledecky and Caeleb Dressel,” said Margo McIlvaine, Brand Manager Reese’s. “These three know exactly what it takes to be the ultimate, and we welcome them to the Ultimate Team Reese’s.”

This summer, as part of Reese’s support of Team USA and the Olympic Games, the brand unveiled Reese’s Ultimate Peanut Butter Lovers Cups. For the first time ever, in its more than 90-year history, the brand released the most extreme, peanut buttery candy version of its iconic Peanut Butter Cups by removing the chocolate! Yes, that’s right, no chocolate. The Reese’s Ultimate Peanut Butter Lovers Cups are here for a limited time only along with returning fan favorite, Reese’s Peanut Butter Lovers Cup.

Throughout the summer, the Reese’s brand will be using their social media pages and fanbase to support the much-anticipated Olympic Games and Team USA. While Reese’s and Team USA fans won’t be seeing 23x U.S. Olympic Gold Medalist Michael Phelps in the pool this Summer, they can catch him in the latest Reese’scommercial featuring our limited-edition Reese’s Ultimate Peanut Butter Lovers Cups.

Reese’s Ultimate Peanut Butter Lovers Cups are being rolled out in standard (1.4oz, SRP $1.09), king size (2.8oz, SRP $1.79) and miniatures (9.3oz, SRP $4.09) at retailers nationwide starting now for a limited time.

For more information or to buy Reese’s Ultimate Lovers Cups, please visit our website.

The Hershey Company and Reese’s brand are a proud partner of Team USA.

About The Hershey Company

The Hershey Company is headquartered in Hershey, Pa., and is an industry-leading snacks company known for bringing goodness to the world through its iconic brands, remarkable people and enduring commitment to help children succeed. Hershey has approximately 17,000 employees around the world who work every day to deliver delicious, quality products. The company has more than 90 brands around the world that drive more than $8 billion in annual revenues, including such iconic brand names as Hershey’s, Reese’s, Kit Kat®, Jolly Rancher, Ice Breakers, SkinnyPop, and Pirate’s Booty.

For more than 125 years, Hershey has been committed to operating fairly, ethically and sustainably.  Hershey founder, Milton Hershey, created the Milton Hershey School in 1909 and since then the company has focused on helping children succeed.

To learn more visit www.thehersheycompany.com

Follow: 
Twitter
LinkedIn
Facebook
YouTube
Instagram 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/reeses-brand-creates-the-ultimate-team-to-support-the-ultimate-cup-301266823.html

SOURCE The Hershey Company

Uber, PayPal and Walgreens Introduce Vaccine Access Fund

New fund allows customers to donate directly to efforts for COVID-19 vaccine access in underserved communities

Uber introduces new in-app donate feature powered by PayPal

PR Newswire

SAN JOSE, Calif., April 12, 2021 /PRNewswire/ — Today, PayPal Holdings, Inc. (NASDAQ: PYPL), Uber Technologies, Inc. (NYSE: UBER) and Walgreens Boots Alliance, Inc. (NASDAQ: WBA) launched their new Vaccine Access Fund that allows customers to donate to vaccine access efforts to help connect people without transportation to COVID-19 vaccination sites, particularly those in underserved communities. Additionally, starting today customers can donate to the Vaccine Access Fund directly through the Uber app using a new donate feature supported by PayPal Giving Fund.

Almost half of Americans do not have access to public transportation, and millions of them miss doctor’s appointments every year because they do not have transportation. In underserved communities, which have been hardest hit by the pandemic, the lack of transportation is of particular concern. To address this, Uber, PayPal and Walgreens are joining forces to help ensure transportation is not a barrier to vaccine access, as we navigate an inclusive recovery from COVID-19.

The coalition – comprised of Uber, PayPal and Walgreens – is donating $11 million dollars to the Vaccine Access Fund to provide free rides for people in underserved communities to get to a vaccination site, and today, the coalition is calling on customers to help too. People can support the Vaccine Access Fund by donating to PayPal Giving Fund, which is a registered 501(c)(3) charity, by visiting: https://www.paypal.com/vaccineaccessfund.

Donations to the Vaccine Access Fund will be granted to and managed by Local Initiatives Support Corporation (LISC), a national community development organization. LISC will identify and work with local nonprofits and other partners that will coordinate free rides for people in their communities, as part of broader efforts around vaccine education and equity. Any surplus of funds will be used to continue the coalition’s commitment to help advance health equity, including ensuring people in underserved communities do not miss medical appointments due to lack of transportation.

Uber is also introducing its new seamless donate feature, which lets customers donate to the cause with a few taps in the Uber app. To donate through the Uber app, customers simply open their Uber or Uber Eats app, tap the donate message and choose their donation amount. Uber is leveraging PayPal’s giving platform, and donations will be made to PayPal Giving Fund to support the Vaccine Access Fund.

Today’s news follows the call to action issued by the White House in February and the initial announcement that Uber, PayPal and Walgreens are building a coalition to increase access to vaccines, with a focus on addressing the needs of underserved communities. PayPal also announced at this time it was making a corporate donation of $5 million to fund additional free or discounted rides. For more information on equitable vaccine access and how you can help, visit: https://www.uber.com/us/en/coronavirus/ or to donate visit: https://www.paypal.com/vaccineaccessfund.

About PayPal
PayPal has remained at the forefront of the digital payment revolution for more than 20 years. By leveraging technology to make financial services and commerce more convenient, affordable, and secure, the PayPal platform is empowering more than 377 million consumers and merchants in more than 200 markets to join and thrive in the global economy. For more information, visit paypal.com.

About Uber

Uber’s mission is to create opportunity through movement. We started in 2010 to solve a simple problem: how do you get access to a ride at the touch of a button? More than 15 billion trips later, we’re building products to get people closer to where they want to be. By changing how people, food, and things move through cities, Uber is a platform that opens up the world to new possibilities.

PayPal Media Contact
Juliet Niczewicz
[email protected]

Uber Media Contact
Andrew Hasburn
[email protected]

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/uber-paypal-and-walgreens-introduce-vaccine-access-fund-301266822.html

SOURCE PayPal Holdings, Inc.

Cushman & Wakefield Named “All Star” by IAOP®, Earns “Sustained Excellence” Distinction in Outsourcing

Cushman & Wakefield Named “All Star” by IAOP®, Earns “Sustained Excellence” Distinction in Outsourcing

CHICAGO–(BUSINESS WIRE)–
Cushman & Wakefield (NYSE: CWK) announced today that the firm earned an All Star distinction from IAOP® for receiving top scores across each major judging category of The 2021 Global Outsourcing 100® list. Additionally, the firm received a Sustained Excellence distinction for having recently been named to the list for the 10th consecutive year.

The real estate services firm earned a perfect score in the Customer References category, the single most important factor in a company’s overall score, for demonstrated results and value created for the firm’s top customers. Cushman & Wakefield also earned top marks in Awards and Certifications, Programs for Innovation and Corporate Social Responsibility (CSR), all of which are increasingly central to customers’ outsourcing decisions.

“We’re pleased that Cushman & Wakefield continued to earn top marks across all judging categories for IAOP’s Global Outsourcing 100 list, particularly for customer references,” said Bill Knightly, Chief Executive of Global Occupier Services (GOS) at Cushman & Wakefield. “We’re committed to bringing the best of our business to each client relationship, from delivering innovative, data-driven solutions to retaining the best people in the industry. These scores are indicative of our dedication to service excellence.”

While the past year was challenging for many of Cushman & Wakefield’s clients, the firm’s frontline property and facility managers and client-facing employees across GOS and C&W Services globally went above and beyond their regular scope of work to keep businesses and communities safe and operational.

“Choosing the right partners is more important than ever. Buyers understand there are hundreds of qualified service providers and advisors out there, but what they need to understand now is what makes each one exceptional,” said Debi Hamill, IAOP CEO. “The Global Outsourcing 100 has done just that, and we’re proud to recognize Cushman & Wakefield.”

The 2021 Global Outsourcing 100 recognizes the world’s best outsourcing service providers and advisors. This list is based on applications received; judging is based on a rigorous scoring methodology that includes an independent review by an independent panel of IAOP customer members with extensive experience in selecting outsourcing service providers and advisors for their organizations.

About Cushman & Wakefield

Cushman & Wakefield (NYSE: CWK) is a leading global real estate services firm that delivers exceptional value for real estate occupiers and owners. Cushman & Wakefield is among the largest real estate services firms with approximately 50,000 employees in over 400 offices and 60 countries. In 2020, the firm had revenue of $7.8 billion across core services of property, facilities and project management, leasing, capital markets, valuation and other services. To learn more, visit www.cushmanwakefield.com or follow @CushWake on Twitter.

About IAOP

IAOP is the global association that brings together customers, providers, and advisors in a collaborative, knowledge-based environment that promotes professional and organizational development, recognition, certification, and excellence to improve business service models and outcomes. Our members and affiliates worldwide are digging deep at IAOP conferences, learning at IAOP chapter meetings, getting trained and certified at IAOP courses and workshops, and connecting through IAOP social media, all with one goal: better business results. Whether you are a customer, provider or advisor, new to collaborative business models like outsourcing, or you are an experienced professional, IAOP connects you and your organization to our growing global community and the resources you need to get the results your company deserves and demands. For more information and how you can become involved, visit www.IAOP.org.

MEDIA CONTACT

Grace Wilk

Corporate Communications, Cushman & Wakefield

+1 312 470 1848

[email protected]

Kate Tulloch-Hammond

Director, Media & Communications, IAOP

+1 845 452 0600, ext. 122

[email protected]

KEYWORDS: United States North America Illinois

INDUSTRY KEYWORDS: Residential Building & Real Estate Commercial Building & Real Estate Construction & Property REIT

MEDIA:

Logo
Logo

CarMax and Dunkin’ are “Doin’ Donuts” for New 24-Hour Test Drive Experience

CarMax and Dunkin’ are “Doin’ Donuts” for New 24-Hour Test Drive Experience

Test Drive Customers Will Receive a $10 Dunkin’ Gift Card and the Chance to Win Free Donuts for a Year

RICHMOND, Va.–(BUSINESS WIRE)–
Today CarMax, Inc. (NYSE: KMX), the nation’s largest retailer of used cars, and Dunkin’, America’s favorite all-day, everyday stop for coffee and baked goods, are inviting people to “do donuts” during their 24-Hour Test Drive — the delicious kind with frosting and sprinkles. Starting today through May 16, CarMax customers who participate in the 24-Hour Test Drive will receive a $10 Dunkin’ gift card to keep their daily routine running during their test drive — and that, of course, means a trip to the Dunkin’ drive-thru for their favorite coffee and donut order.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210412005143/en/

(Photo: Business Wire)

(Photo: Business Wire)

“At CarMax, we believe the car-buying experience should be as enjoyable as possible while ensuring customers feel confident with their decision, which is why we introduced 24-Hour Test Drives as part of CarMax’s Love Your Car Guarantee,” said Sarah Lane, vice president, marketing at CarMax. “We want customers to experience a day in their life with their new ride, and since America Runs on Dunkin’, we know that includes a trip through the Dunkin’ drive-thru for their favorite order. Collaborating with Dunkin’ on Doin’ Donuts makes CarMax’s 24-Hour Test Drive experience that much sweeter.”

Customers at participating CarMax locations who take a 24-Hour Test Drive will receive a creative checklist of ideas to help ensure they are getting the most out of their 24 hours — such as taking their dog for a drive, packing the trunk with their favorite cargo to ensure it fits and, of course, visiting a drive-thru to make sure the cup holder can fit their Dunkin’ Iced Coffee. Customers who share about their 24-Hour Test Drive experience on Twitter or Instagram by tagging @CarMax, #DoinDonuts, and #24HrTestDrive can participate in a sweepstakes in which 24 people have the chance to win free donuts for a year and a “Doin’ Donuts” signature donut holder. More information on official rules, eligibility and participating locations can be found at carmax.com/doindonuts.

“You never truly know if a car is right for you until you’ve taken it through a Dunkin’ drive-thru,” said Melanie Rabino, director, brand engagement at Dunkin’. “Making sure your new vehicle’s cup holders perform perfectly in holding your Dunkin’ Iced Coffee, or other go-to order, is the perfect test.”

Actress, New York Times best-selling author, and podcast host Busy Philipps is also joining in on the fun. She’s as busy as ever, and with a CarMax 24-Hour Test Drive, she can take her test drive on the go. Whether she’s running errands or headed to her next acting gig, Busy is demonstrating via Instagram what she recommends doing during a test drive to ensure a car meets all her needs before committing. And of course she can’t start the day without a pick-me-up from Dunkin’.

“Everyone wants to be in control of their car buying decisions,” said Busy Philipps. “CarMax not only made my experience fun, but they also provided ease and confidence with a 24-Hour Test Drive fueled by Dunkin’. Having the car for a full day gave me the ability to see and learn every feature and how it seamlessly fit into my busy schedule.”

CarMax’s 24-Hour Test Drive offering is a part of the company’s signature experience — the Love Your Car Guarantee — providing unrivaled peace of mind and buyer confidence as customers experience a day in their life with a new ride prior to purchase. CarMax’s Love Your Car Guarantee also includes a 30-Day Money Back Guarantee, giving customers 30 days to fall in love with their car or return it for a full refund up to 1,500 miles. This offering is unmatched in the automotive industry.

For official rules, participating locations and more information on “Doin’ Donuts,” visit carmax.com/doindonuts.

About CarMax

CarMax, the nation’s largest retailer of used cars, revolutionized the automotive retail industry by driving integrity, honesty and transparency in every interaction. The company offers a truly personalized experience with the option for customers to do as much, or as little, online and in-store as they want. CarMax also provides a variety of vehicle delivery methods, including home delivery, contactless curbside pickup and appointments in its stores. During the fiscal year ending February 28, 2021, CarMax sold more than 750,000 used cars and more than 425,000 wholesale vehicles at its in-store and virtual auctions. In addition, CarMax Auto Finance originated more than $6 billion in auto receivables during fiscal year 2021, adding to its near $14 billion portfolio. CarMax has 220 stores, over 25,000 Associates, and is proud to have been recognized for 17 consecutive years as one of the Fortune 100 Best Companies to Work For®. For more information, visit www.carmax.com.

About Dunkin’

Founded in 1950, Dunkin’ is America’s favorite all-day, everyday stop for coffee and baked goods. Dunkin’ is a market leader in the hot regular/decaf/flavored coffee, iced regular/decaf/flavored coffee, donut, bagel and muffin categories. Dunkin’ has earned a No. 1 ranking for customer loyalty in the coffee category by Brand Keys for 15 years running. The company has more than 12,600 restaurants in 40 countries worldwide. Dunkin’ is part of the Inspire Brands family of restaurants. For more information, visit www.DunkinDonuts.com.

Media:

CarMax

Lindsey Duke

[email protected]

855-887-2915

Dunkin’

Caroline Medeiros

[email protected]

781-737-5200

The Martin Agency

Ellie McNevin

[email protected]

917-655-3111

KEYWORDS: Virginia United States North America

INDUSTRY KEYWORDS: Social Media Retail Marketing General Entertainment Communications Other Consumer Women Convenience Store Men General Automotive LGBTQ+ Family Automotive Entertainment Food/Beverage Consumer

MEDIA:

Photo
Photo
(Photo: Business Wire)

KDMN Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Kadmon Holdings, Inc.Investors of Class Action and Encourages Shareholders to Contact the Firm

KDMN Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Kadmon Holdings, Inc.Investors of Class Action and Encourages Shareholders to Contact the Firm

NEW YORK–(BUSINESS WIRE)–
Attorney Advertising–Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Kadmon Holdings, Inc. (“Kadmon” or the “Company”) (NASDAQ: KDMN) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Kadmon securities between October 1, 2020 and March 10, 2021, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/kdmn.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and failed to disclose that: (1) the Belumosudil NDA was incomplete and/or deficient; (2) the additional new data that the Company submitted in support of the Belumosudil NDA in response to an information request from the FDA materially altered the NDA submission; (3) accordingly, the initial Belumosudil NDA submission lacked the degree of support that the Company had led investors to believe; (4) accordingly, the FDA was likely to extend the PDUFA target action date to review the Belumosudil NDA; and (5) as a result, the Company’s public statements were materially false and misleading at all relevant times.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/kdmnor you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Kadmon you have until June 2, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Hurwitz

212-697-6484 | [email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Logo
Logo

GOEV Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Canoo Inc.Investors of Class Action and Encourages Shareholders to Contact the Firm

GOEV Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Canoo Inc.Investors of Class Action and Encourages Shareholders to Contact the Firm

NEW YORK–(BUSINESS WIRE)–
Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Canoo Inc. (“Canoo” or the “Company”) (NASDAQ: GOEV) f/k/a Hennessy Capital Acquisition Corp. IV (“Hennessy Capital”) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Canoo securities between August 18, 2020 and March 29, 2021, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/goev.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and failed to disclose that: (1) Canoo had decreased its focus on its plan to sell vehicles to consumers through a subscription model; (2) Canoo would de-emphasize its engineering services business; (3) contrary to prior statements, Canoo did not have partnerships with original equipment manufacturers and no longer engaged in the previously announced partnership with Hyundai; and (4) as a result, Defendants’ statements about its business, operations, and prospects were materially false and misleading and/or lacked reasonable basis at all relevant times.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/goevor you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Canoo you have until June 1, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Hurwitz

212-697-6484 | [email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Logo
Logo

MPLN Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies MultiPlan Corporation Investors of Class Action and Encourages Shareholders to Contact the Firm

MPLN Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies MultiPlan Corporation Investors of Class Action and Encourages Shareholders to Contact the Firm

NEW YORK–(BUSINESS WIRE)–
Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against MultiPlan Corporationf/k/a Churchill Capital Corp. III (“Churchill III”) (“MultiPlan” or the “Company”) (NASDAQ: MPLN) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired MultiPlan securities between July 12, 2020 and November 10, 2020, inclusive (the “Class Period”) and on behalf of all holders of Churchill III Class A common stock entitled to vote on Churchill III’s merger with and acquisition of Polaris Parent Corp. and its consolidated subsidiaries (collectively, “MultiPlan”), which merger was consummated in October 2020 (the “Merger”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/mpln.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, and failed to disclose material adverse facts to investors.

This complaint alleges that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) MultiPlan was losing tens of millions of dollars in sales and revenues to Naviguard, a competitor created by one of MultiPlan’s largest customers, UnitedHealthcare, which threatened up to 35% of MultiPlan’s sales and 80% of its levered cash flows by 2022; (2) sales and revenue declines in the quarters leading up to the Merger were not due to “idiosyncratic” customer behaviors as represented, but rather due to a fundamental deterioration in demand for MultiPlan’s services and increased competition, as payors developed competing services and sought alternatives to eliminating excessive healthcare costs; (3) MultiPlan was facing significant pricing pressures for its services and had been forced to materially reduce its take rate in the lead up to the Merger by insurers, who had expressed dissatisfaction with the price and quality of MultiPlan’s services and balanced billing practices, causing MultiPlan to cut its take rate by up to half in some cases; (4) as a result, MultiPlan was set to continue to suffer from revenues and earnings declines, increased competition and deteriorating pricing dynamics following the Merger; (5) consequently, MultiPlan was forced to seek continued revenue growth and to improve its competitive positioning through pricey acquisitions, including through the purchase of the healthcare technology company HST for $140 million at a premium price from a former MultiPlan executive only one month after the Merger; and (6) as such, Churchill III investors had grossly overpaid for the acquisition of MultiPlan in the Merger, and MultiPlan’s business was worth far less than represented to investors.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/mplnor you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in MultiPlan you have until June 7, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Hurwitz

212-697-6484 | [email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Logo
Logo

SOS Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies SOS Limited Investors of Class Action and Encourages Shareholders to Contact the Firm

SOS Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies SOS Limited Investors of Class Action and Encourages Shareholders to Contact the Firm

NEW YORK–(BUSINESS WIRE)–
Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against SOS Limited (“SOS” or “the Company”) (NYSE: SOS) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired SOS American depository shares (“ADSs”) between July 22, 2020 and February 25, 2021, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/sos.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and failed to disclose that: (1) SOS had misrepresented the true nature, location, and/or existence of at least one of the principal executive offices listed in its SEC filings; (2) HY and FXK were either undisclosed related parties and/or entities fabricated by the Company; (3) the Company had misrepresented the type and/or existence of the mining rigs that it claimed to have purchased; and (4) as a result, the Company’s public statements were materially false and misleading at all relevant times.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site:www.bgandg.com/sosor you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in SOS you have until May 31, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Hurwitz

212-697-6484 | [email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Logo
Logo

Vita Frute introduces original mix 12-pack and new Blood Orange flavor for the spring

PR Newswire

ST. LOUIS, April 12, 2021 /PRNewswire/ — As the weather warms up, Vita Frute Vodka Soda is providing cool adult refreshment with its new original mix 12-pack featuring the latest Vita Frute flavor, Blood Orange. Blood Orange, with its citrusy, refreshing tang, also will be available in a 4-pack. Just like the original Vita Frute Vodka Soda, Blood Orange is crafted with American-made vodka, club soda and all-natural flavors.

“The market for single-serve hard seltzer beverages continues to expand exponentially year over year,” said Chelsi Hofmeister, assistant brand manager for Vita Frute. “We are meeting this growing demand by giving adult consumers what they want: fresh, new flavors and mixed packs of their favorites.”

According to recent Nielsen data, in 2020 the hard seltzer category continued to grow at a rapid pace – seeing 136% growth over the prior year – and is on pace to double by 2022. Vita Frute’s product additions provide producer Luxco with the opportunity to innovate in an emerging category and to expand distribution at retail.

The Vita Frute Original Mix 12-Pack includes the following flavors: Lime Basil, Pineapple Coconut, Grapefruit, and new Blood Orange. All Vita Frute flavors are 5% ABV, making them perfect to drink on their own or add to a cocktail.

The retail creative will continue to reinforce Vita Frute’s key attributes: 100 calories, zero sugar, gluten free, vegan friendly and all-natural flavors – messages that resonate with the brand’s target market: health-conscious adults aged 21 to 35.

The new Vita Frute Original Mix 12-Pack and Blood Orange 4-Pack are competitively priced with other products in the hard seltzer category and will be available nationwide beginning this month. For more information about Vita Frute and cocktail inspiration, or to find a retailer, visit vitafrute.com.

About Luxco

Founded in St. Louis in 1958 by the Lux Family, Luxco is a leading producer, supplier, importer and bottler of beverage alcohol products. Our mission is to meet the needs and exceed the expectations of consumers, associates and business partners. Merged with MGP Ingredients, Inc. in 2021 (Nasdaq: MGPI), Luxco operates as MGP’s Brands Division and manages all MGP/Luxco brands. This extensive and award-winning spirits portfolio includes well-known brands from five distilleries: Bardstown, Kentucky-based Lux Row Distillers, home of Ezra Brooks, Rebel, Blood Oath, David Nicholson and Daviess County; Lebanon, Kentucky-based Limestone Branch Distillers, maker of Yellowstone Kentucky Straight Bourbon Whiskey, Minor Case Straight Rye Whiskey and Bowling & Burch Gin; Jalisco, Mexico-based Destiladora González Lux, producer of 100% agave tequilas, El Mayor, Exotico and Dos Primos; MGP’s historic distillery in Lawrenceburg, Indiana, where the George Remus Straight Bourbon Whiskey and Rossville Union Straight Rye Whiskey are produced; and the Washington, D.C.-based Green Hat Distillery, producer of the Green Hat family of gins. The innovative and high-quality brand portfolio also includes Everclear Grain Alcohol, Pearl Vodka, Saint Brendan’s Irish Cream, The Quiet Man Irish Whiskey and other well-recognized brands. For more information about the company and its brands, visit luxco.com.

CONTACT:

Patrick Barry, BYRNE PR
314-540-3865
[email protected] 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/vita-frute-introduces-original-mix-12-pack-and-new-blood-orange-flavor-for-the-spring-301266833.html

SOURCE Luxco

DiaSorin to acquire Luminex Corporation for USD 37.00 per share or approximately USD 1.8 billion

IMPORTANT NOTICE

By reading the following release, you further agree to be bound by the following limitations and qualifications:

This communication is for informational purposes only and is not intended to and does not constitute an offer or invitation to exchange or sell or solicitation of an offer to subscribe for or buy, or an invitation to exchange, purchase or subscribe for, any securities, any part of the business or assets described herein, or any other interests or the solicitation of any vote or approval in any jurisdiction in connection with the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. This communication should not be construed in any manner as a recommendation to any reader of this communication.

This communication is not a prospectus, product disclosure statement or other offering document for the purposes of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017.

– Provides Access To Proven Luminex Multiplexing Technology And Molecular Testing Solutions To Be Used In Unique Testing Panels, Generating Critical Mass In The Molecular Diagnostics Space

– Sets The Ground For New Partnerships And Business Development Opportunities Through Life Science Offerings

– Broadens DiaSorin’s Presence In The U.S.

– Accelerates Luminex Technology And Solutions’ Penetration Outside The U.S. By Leveraging DiaSorin’s International Commercial Footprint

– Creates Significant Value And Is Expected To Be Immediately Accretive To DiaSorin Earnings Per Share(1) post Closing

PR Newswire

SALUGGIA, Italy, April 11, 2021 /PRNewswire/ — DiaSorin S.p.A. (“DiaSorin“; FTSE MIB: DIA) today announced that its Board of Directors has unanimously approved and signed a definitive merger agreement for DiaSorin to acquire Luminex Corporation (“Luminex“; NASDAQ: LMNX) for a price of USD 37.00 per share in an all-cash transaction. This corresponds to a total equity value of approximately USD 1.8 billion on a fully diluted basis and an enterprise value of approximately USD 1.8 billion.

The cash consideration represents a c.23.1% premium to Luminex shareholders based on the unaffected closing stock price of Luminex on 24 February 2021 (the date prior to press rumors regarding a potential sale of the company) and a c.30.6% and c.47.5% premium, based on, respectively, the 30-day and 90-day volume-weighted average closing stock price before 24 February 2021.

Luminex develops, manufactures and sells proprietary biological testing technologies and products with leading applications throughout the Diagnostics and Life Science industries. Luminex is a leader in multiplexing technology, one of the fastest growing markets in the molecular space, with more than 900 active clients. With its first-class technology and extensive Life Science solutions supporting clinical and pharmaceutical research and development, Luminex is highly complementary to DiaSorin’s growing diagnostics segment.

The acquisition will broaden DiaSorin’s positioning in the molecular diagnostics space and strengthen its existing value proposition in line with its strategic priorities. Through the acquisition, DiaSorin will gain access to Luminex’s molecular diagnostics multiplexing technology and a portfolio that will strengthen its existing offering while expanding its presence in the U.S. The acquisition will also provide access to Luminex’s applications throughout the Life Science industry, supporting access to academic and scientific research to shape market intelligence on future market trends, engaging with biopharma companies to drive opportunities for long-term partnerships (e.g. vaccine development, biological drugs) and access to clinical multiplexing assays for future Value Based Care projects based on diagnostic algorithms, as defined at the 2019 DiaSorin Investor Day.

Following the acquisition, the combined entity will have combined 2020 revenues(2) of approximately € 1.25 billion, adjusted EBITDA(3) of approximately € 472 million, and positive Net Financial Position(4) of approximately € 335 million.

“We are really excited about this transaction, which we believe creates value for our shareholders and represents an outstanding opportunity for our future growth, positioning DiaSorin and Luminex as a unique combination of diagnostic specialists,” said Carlo Rosa, CEO of DiaSorin Group. “Luminex perfectly fits with our strategy to grow our positioning in the molecular diagnostics space, to broaden our presence in the U.S., and to create additional value through Life Science offerings. Together, DiaSorin and Luminex will provide a unique offer to laboratories, researchers, clinicians and patients worldwide, matching our extensive solutions in immunodiagnostics and molecular diagnostics with Luminex’s outstanding expertise in multiplexing technology and recognized leadership in life science applications. We look forward to having DiaSorin and Luminex employees working together for an exciting new journey.”

With the merger into DiaSorin, we believe we can expand the value our customers receive through an expanded global product and service portfolio. The proposed transaction underscores the respected position Luminex has built in the marketplace and rewards our shareholders with attractive value for their shares,” said Nachum “Homi” Shamir, Chairman, President and CEO of Luminex. “The combined company should provide new opportunities for our employees within a larger company that is poised to become a strong leader in the molecular diagnostics and life sciences space, and I want to thank all of our employees, customers, and partners for their contributions over our 25+ year history.

RATIONALE FOR THE ACQUISITION AND STRATEGIC BENEFITS OF THE TRANSACTION

  • Provides access to leading multiplexing technology and molecular testing solutions to be used in unique testing panels: Luminex’s top-notch, flexible and leading multiplexing technology will strengthen DiaSorin’s offering in the molecular diagnostics space. DiaSorin will access a unique and extensive menu of solutions in Infectious Diseases, Respiratory Infections, Vector-Borne, Hospital Acquired Infections, Gastroenterology Infections, Genetics, and Women’s health.
  • Sets the ground for new partnerships and business development opportunities through Life Science offerings: Access to academic and scientific research will allow DiaSorin to shape market intelligence based on future market trends, engaging with Biopharma companies to drive opportunities for long-term partnerships (e.g. vaccine, biological drugs) and creating new future Value Based Care opportunities based on diagnostic algorithms, as defined at the 2019 DiaSorin Investor Day.
  • Broadens DiaSorin’s presence in the U.S.: Luminex’s strong positioning in the U.S. will allow DiaSorin to offer an enhanced and more diverse product mix in the biggest diagnostics market in the world and the most rewarding for innovation.
  • Accelerates Luminex technology and solutions’ penetration outside the U.S. through DiaSorin’s extensive commercial and geographical reach: Luminex will leverage DiaSorin’s leadership position, generating additional and sustainable long-term growth.
  • Creates significant value to shareholders: Immediately accretive to DiaSorin earnings per share(1) post closing, attractive return on invested capital profile and significant cost synergies generate value to current and future shareholders.

TRANSACTION CONSIDERATIONS

Under the terms of the agreement, Luminex will be merged with a newly formed U.S. subsidiary of DiaSorin, with Luminex shareholders receiving USD 37.00 in cash for each of their Luminex shares.

The transaction is expected to close within the third quarter of 2021 and is subject to Luminex shareholder approval and to other customary closing conditions, including the satisfaction of antitrust and CFIUS regulatory requirements.

The transaction will be funded through a mix of cash and external financing. Specifically, DiaSorin signed today a Senior Facilities Agreement with a syndicate of banks (consisting of BNP Paribas, Citi, Mediobanca and UniCredit) providing for a term loan of USD 1.1 billion due on 2026 and a bridge loan of USD 500 million due within 12 months, with extension options (exercisable at DiaSorin’s discretion) for an additional 12 months. With regard to the bridge facility, DiaSorin will evaluate different take-out alternatives.

Combined entity leverage(5) of the transaction is estimated to be approximately 2.5x and is expected to quickly decrease driven by cash generation of the combined entity.

The transaction will be immediately accretive to DiaSorin’s earnings per share(1) following closing of the transaction and will generate an attractive return on invested capital profile. The combination is also anticipated to result in cost synergies of approximately USD 55 million within 3 years after closing.

ADVISORS

Morgan Stanley & Co. International PLC acted as lead financial advisor to DiaSorin and Cravath Swaine & Moore LLP and Pedersoli Studio Legale acted as legal advisors. Perella Weinberg Partners acted as financial advisor to Luminex Corporation and DLA Piper LLP (US) acted as legal advisor. Mediobanca – Banca di Credito Finanziario S.p.A. provided a fairness opinion to the Board of Directors of DiaSorin. 

Citigroup Global Markets Europe AG acted as financial advisor to DiaSorin. Citibank., N.A., London Branch also acted as a Bookrunner and Mandated Lead Arranger for the USD 1.6 billion fully committed Senior Facilities Agreement (“SFA”). BNP Paribas, Italian Branch, Mediobanca – Banca di Credito Finanziario S.p.A. and UniCredit S.p.A. are also Bookrunners and Mandated Lead Arrangers under the SFA; Mediobanca – Banca di Credito Finanziario S.p.A. is Agent for the SFA. In connection with the SFA, Cravath Swaine & Moore LLP, Pedersoli Studio Legale and Slaughter and May have acted as legal advisors to DiaSorin and Clifford Chance acted as legal advisor to the lenders.

CONFERENCE CALL

Presentation slides are available at the following link https://diasoringroup.com/en/investors/financial-corner/presentations and on the centralized storage of regulated information denominated eMarket STORAGE, available at the website www.emarketstorage.com.

A replay and the transcript of the call will be available after the conference call in that section of DiaSorin’s website.

NEW DIASORIN’S INVESTOR DAY

Save the date: DiaSorin will host a new Investor Day by the end of September 2021.

ABOUT DIASORIN
Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field, with 26 companies, 4 branches, 5 manufacturing facilities and 5 research and development centers.

For over 50 years, DiaSorin has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide. The extensive diagnostic testing offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the “Diagnostic Specialist”.

More info at www.diasoringroup.com


For additional information, please contact:


INVESTOR RELATIONS CONTACTS


Riccardo Fava


Emanuela Salvini


Corporate Vice President Communication & Investor Relations


Investor Relator

Tel: +39 0161.487988

Tel: +39 0161.487567


[email protected] 


[email protected] 


U.S. Media Contacts


Mary K. Conway                                                                                                                 

Tel: +1 516.606.6545                                                                                                             


[email protected]

Forward-Looking Statement

This communication contains forward-looking statements, including within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the U.S. Securities Exchange Act of 1934. We intend the forward-looking statements contained in this communication to be covered by the safe harbor provisions of such Acts.  All statements other than statements of historical fact in this communication are “forward-looking statements” for purposes of such Acts.  In particular, these forward-looking statements include statements regarding future financial performance and the expectations of DiaSorin and Luminex (the “Parties“) as to, among other things, the achievement of certain targeted metrics at any future date or for any future period are forward-looking statements. These statements may include terms such as “may”, “will”, “expect”, “could”, “should”, “intend”, “estimate”, “anticipate”, “believe”, “remain”, “on track”, “design”, “target”, “objective”, “goal”, “forecast”, “projection”, “outlook”, “prospects”, “plan”, or similar terms. Forward-looking statements are not guarantees of future performance. Rather, they are based on the Parties’ current state of knowledge, future expectations and projections about future events and are by their nature, subject to inherent risks and uncertainties. They relate to events and depend on circumstances that may or may not occur or exist in the future and, as such, undue reliance should not be placed on them.

Actual results may differ materially from those expressed in forward-looking statements as a result of a variety of factors, including: the impact of the COVID-19 pandemic, the ability of DiaSorin and Luminex and/or the combined entity resulting from the proposed transaction (together with the Parties, the “Companies“) to create and launch new products successfully; changes in the global financial markets, general economic environment and changes in demand for diagnostic/healthcare/life sciences products, which is subject to cyclicality; changes in local economic and political conditions, changes in trade policy and the imposition of global and regional tariffs or tariffs targeted to the diagnostic/healthcare/life sciences industry, the enactment of tax reforms or other changes in tax laws and regulations; the Companies’ ability to offer innovative, attractive products; various types of claims, lawsuits, governmental investigations and other contingencies, including product liability and warranty claims, investigations and lawsuits; material operating expenditures in relation to compliance with health and safety regulations; the intense level of competition in the rapidly-changing diagnostic/healthcare/life sciences industry, which may increase due to consolidation; exposure to shortfalls in the funding of the Parties’ defined benefit pension plans; the ability to access funding to execute the Companies’ business plans and improve their businesses, financial condition and results of operations; the Companies’ ability to realize anticipated benefits from joint venture arrangements; disruptions arising from political, social and economic instability; commercial risk due the fact that the Companies operate in a market characterized by the presence of large competitors; risk associated to the maintenance of relationship with customers and strategic partners; risks associated with our relationships with employees and suppliers; increases in costs, disruptions of supply or shortages of raw materials; developments in labor and industrial relations and developments in applicable labor laws; exchange rate fluctuations, interest rate changes, credit risk and other market risks; political and civil unrest; earthquakes or other disasters; uncertainties as to whether the proposed acquisition discussed in this communication will be consummated or as to the timing thereof; the risk that the announcement of the proposed acquisition may make it more difficult for the Parties to establish or maintain relationships with their employees, suppliers and other business partners or governmental entities; the risk that the businesses of the Parties will be adversely impacted during the pendency of the proposed acquisition; risks related to the regulatory approvals necessary for the combination; the risk that the operations of DiaSorin and Luminex will not be integrated successfully and other risks and uncertainties; and such other factors relating to Luminex discussed in its Annual Report on Form 10-K for the fiscal year ended December 31, 2020, and, in particular, the risks discussed under the caption “Item 1A. Risk Factors”, filed with the U.S. Securities Exchange Commission (the “SEC“).

Any forward-looking statements contained in this communication speak only as of the date of this document and the Parties disclaim any obligation to update or revise publicly forward-looking statements. Further information concerning the Parties and their businesses, including factors that could materially affect the Parties’ financial results, are included in DiaSorin’s reports and filings with CONSOB and Borsa Italiana and Luminex’s filings and reports with the SEC.

No responsibility.  DiaSorin is in no way responsible for the accuracy, completeness and truthfulness of the data and information relating to Luminex, contained in and/or used for the purposes of this communication and Luminex is in no way responsible for the accuracy, completeness and truthfulness of the data and information contained in and/or used for the purposes of this communication.

No update. The information and opinions in this communication is provided to you as of the dates indicated and DiaSorin and Luminex do not undertake to update the information contained in this communication and/or any opinions expressed relating thereto after its presentation, even in the event that the information becomes materially inaccurate, except as otherwise required by applicable laws.

Non-IFRS and Other Performance Measures. This communication contains certain items as part of the financial disclosure which are not defined under IFRS. Accordingly, these items do not have standardized meanings and may not be directly comparable to similarly-titled items adopted by other entities. DiaSorin management has identified a number of “Alternative Performance Indicators” (“APIs“). These APIs (i) are derived from historical results of DiaSorin and are not intended to be indicative of future performance, (ii) are non-IFRS financial measures and, although derived from the financial statements, are unaudited and (iii) are not an alternative to financial measures prepared in accordance with IFRS. The APIs presented herein include adjusted EBITDA and Net Financial Position([6]). These measures are not indicative of our historical operating results, nor are they meant to be predictive of future results. These measures are used by our management to monitor the underlying performance of our business and operations. Similarly entitled non-IFRS financial measures reported by other companies may not be calculated in an identical manner, consequently our measures may not be consistent with similar measures used by other companies. Therefore, investors should not place undue reliance on this data.

Important Information For Investors And Shareholders – No Offer To Purchase Or Sell Securities

This communication is for informational purposes only and is not intended to and does not constitute or form a part of an offer or invitation to exchange or sell or solicitation of an offer to subscribe for or buy, or an invitation to exchange, purchase or subscribe for, any securities, any part of the business or assets described herein, or any other interests or the solicitation of any vote or approval in any jurisdiction in connection with the potential transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. This communication should not be construed in any manner as a recommendation to any reader of this communication. No offer of securities shall be made.

This communication is not a prospectus, product disclosure statement or other offering document for the purposes of Regulation (EU) 2017/1129 (this Regulation and amendments together with any delegated act and implementing measures) or any other applicable laws or regulations.

This communication does not represent an offer to the public in Italy, pursuant to Section 1, letter (t) of Legislative Decree no. 58 of February 24, 1998, as subsequently amended and supplemented, nor elsewhere. The release, publication or distribution of this communication in certain jurisdictions may be restricted by law, and therefore persons in such jurisdictions into which this document is released, published or distributed should inform themselves about and observe such restrictions.

Additional Information And Where To Find It

This communication may be deemed to be solicitation material in respect of the proposed transaction between the Parties. In connection with the proposed transaction, Luminex plans to file relevant materials with the SEC, including a proxy statement on Schedule 14A. Promptly after filing its definitive proxy statement with the SEC, Luminex will mail the definitive proxy statement to each shareholder entitled to vote at the special meeting relating to the transaction.  INVESTORS AND SHAREHOLDERS ARE URGED TO CAREFULLY READ THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO AND ANY DOCUMENTS INCORPORATED BY REFERENCE THEREIN) AND ANY OTHER RELEVANT DOCUMENTS IN CONNECTION WITH THE TRANSACTION THAT LUMINEX WILL FILE WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE TRANSACTION AND THE PARTIES TO THE TRANSACTION.  The definitive proxy statement, the preliminary proxy statement and other relevant materials in connection with the transaction (when they become available) and any other documents filed by Luminex with the SEC may be obtained free of charge at the SEC’s website (www.sec.gov), or from Luminex by going to its investor relations website at investor.luminexcorp.com.

DiaSorin, Luminex and their respective directors, executive officers and certain other members of management may be deemed, under SEC rules, to be participants in the solicitation of proxies from Luminex’s shareholders in connection with the transaction.  Information regarding the interests of such individuals in the proposed transaction will be included in the proxy statement relating to such transaction when it is filed with the SEC. You may obtain information about Luminex’s directors and officers in Luminex’s definitive proxy statement for its 2021 annual meeting of shareholders, which was filed with the SEC on March 31, 2021, and in subsequent statements of changes in beneficial ownership on file with the SEC. These documents may be obtained free of charge from the SEC’s website (www.sec.gov).

(1)
 
Including synergies, excluding implementation costs, asset impairment and amortization of acquired intangibles recognized due to acquisition.

(2)

 

Luminex revenues converted at average 2020 exchange rate.

(3)
 
Luminex EBITDA converted at average 2020 exchange rate and restated from US GAAP to IFRS (DiaSorin estimate).

(4)

 

Luminex Net Financial Position at December 31, 2020 converted at average 2020 exchange rate (DiaSorin estimate), without taking into account the external financing to be incurred to fund the acquisition.

(5)
 
Estimated as combined Net Financial Position at December 31, 2020, including the incurrence of the indebtedness necessary to fund the acquisition on combined 2020 adjusted EBITDA.


(6)

 
EBITDA is a non-GAAP measure used by the Companies for measuring performance; EBITDA means the “operating result (EBIT)” before amortization of intangibles and depreciation of property, plant and equipment. Adjusted EBITDA means Luminex EBITDA converted at yearly average exchange rate and restated from US GAAP to IFRS (DiaSorin estimate).

Net Financial Position (debt)
is a non-GAAP measure used by the Companies for measuring the
 financial structure. It is calculated as the “net current financial assets” (i.e. liquid assets + other current financial assets + current financial liabilities) plus the “non-current financial liabilities”.

 

Cision View original content:http://www.prnewswire.com/news-releases/diasorin-to-acquire-luminex-corporation-for-usd-37-00-per-share-or-approximately-usd-1-8-billion-301266829.html

SOURCE DiaSorin